NOREPINEPHRINE BITARTRATE IN 5% DEXTROSE Drug Patent Profile

When do Norepinephrine Bitartrate In 5% Dextrose patents expire, and when can generic versions of Norepinephrine Bitartrate In 5% Dextrose launch?

Norepinephrine Bitartrate In 5% Dextrose is a drug marketed by Baxter Hlthcare Corp and Sagent and is included in two NDAs. There are two patents protecting this drug.

This drug has three patent family members in three countries.

The generic ingredient in NOREPINEPHRINE BITARTRATE IN 5% DEXTROSE is norepinephrine bitartrate. There are five drug master file entries for this compound. Twenty-six suppliers are listed for this compound. Additional details are available on the norepinephrine bitartrate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Norepinephrine Bitartrate In 5% Dextrose

A generic version of NOREPINEPHRINE BITARTRATE IN 5% DEXTROSE was approved as norepinephrine bitartrate by MEITHEAL on March 3^rd, 2003.

Summary for NOREPINEPHRINE BITARTRATE IN 5% DEXTROSE

International Patents:	3
US Patents:	2
Applicants:	2
NDAs:	2
Finished Product Suppliers / Packagers:	1
Clinical Trials:	12
DailyMed Link:	NOREPINEPHRINE BITARTRATE IN 5% DEXTROSE at DailyMed

Recent Clinical Trials for NOREPINEPHRINE BITARTRATE IN 5% DEXTROSE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Visarat Palitnonkiat	PHASE1
Siriraj Hospital	PHASE1
Hassan II University	PHASE4

See all NOREPINEPHRINE BITARTRATE IN 5% DEXTROSE clinical trials

Pharmacology for NOREPINEPHRINE BITARTRATE IN 5% DEXTROSE

Drug Class

Catecholamine

US Patents and Regulatory Information for NOREPINEPHRINE BITARTRATE IN 5% DEXTROSE

NOREPINEPHRINE BITARTRATE IN 5% DEXTROSE is protected by two US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Baxter Hlthcare Corp	NOREPINEPHRINE BITARTRATE IN 5% DEXTROSE	norepinephrine bitartrate	SOLUTION;INTRAVENOUS	214313-001	Jan 15, 2021	AP	RX	Yes	Yes	12,097,170		Y
Sagent	NOREPINEPHRINE BITARTRATE IN 5% DEXTROSE	norepinephrine bitartrate	SOLUTION;INTRAVENOUS	219692-002	Aug 11, 2025	AP	RX	No	No
Baxter Hlthcare Corp	NOREPINEPHRINE BITARTRATE IN 5% DEXTROSE	norepinephrine bitartrate	SOLUTION;INTRAVENOUS	214313-002	Jan 15, 2021	AP	RX	Yes	Yes	12,290,494		Y
Baxter Hlthcare Corp	NOREPINEPHRINE BITARTRATE IN 5% DEXTROSE	norepinephrine bitartrate	SOLUTION;INTRAVENOUS	214313-001	Jan 15, 2021	AP	RX	Yes	Yes	12,290,494		Y
Baxter Hlthcare Corp	NOREPINEPHRINE BITARTRATE IN 5% DEXTROSE	norepinephrine bitartrate	SOLUTION;INTRAVENOUS	214313-002	Jan 15, 2021	AP	RX	Yes	Yes	12,097,170		Y
Sagent	NOREPINEPHRINE BITARTRATE IN 5% DEXTROSE	norepinephrine bitartrate	SOLUTION;INTRAVENOUS	219692-001	Aug 11, 2025	AP	RX	No	No

International Patents for NOREPINEPHRINE BITARTRATE IN 5% DEXTROSE

See the table below for patents covering NOREPINEPHRINE BITARTRATE IN 5% DEXTROSE around the world.

Country	Patent Number	Title	Estimated Expiration
World Intellectual Property Organization (WIPO)	2021178946
Canada	3174640	SYSTEME DE RECIPIENT SCELLE CONDITIONNE DE STOCKAGE STABLE DE FORMULATION PHARMACEUTIQUE SENSIBLE A L'OXYGENE (PACKAGED, SEALED CONTAINER SYSTEM FOR STABLE STORAGE OF AN OXYGEN SENSITIVE PHARMACEUTICAL FORMULATION)
European Patent Office	4114336	SYSTÈME DE RÉCIPIENT SCELLÉ CONDITIONNÉ DE STOCKAGE STABLE DE FORMULATION PHARMACEUTIQUE SENSIBLE À L'OXYGÈNE (PACKAGED, SEALED CONTAINER SYSTEM FOR STABLE STORAGE OF AN OXYGEN SENSITIVE PHARMACEUTICAL FORMULATION)

Market Dynamics and Financial Trajectory for Norepinephrine Bitartrate in 5% Dextrose

Last updated: February 28, 2026

What Drives Market Demand for Norepinephrine Bitartrate in 5% Dextrose?

Norepinephrine Bitartrate in 5% Dextrose functions primarily as a vasopressor used in critical care settings to treat hypotension and shock. Its market depends on critical care hospitalization rates, regulatory approvals, and hospital formulary preferences.

Key Market Drivers:

• Increased prevalence of sepsis and shock cases worldwide.
• Growth in intensive care unit (ICU) admissions, especially in aging populations.
• Regulatory approvals expanding indications.
• Advances in infusion technology facilitating broader hospital use.

Geographic Distribution:

• North America: Largest market, benefiting from high ICU admission rates and established healthcare infrastructure.
• Europe: Significant due to comprehensive critical care protocols.
• Asia-Pacific: Rapid growth driven by expanding healthcare infrastructure and rising sepsis cases.

Market Constraints:

• Pricing pressures in government and private healthcare systems.
• Availability of generic formulations reducing market share for branded drugs.
• Stringent regulatory environments delaying approval processes.

What Are the Financial Projections and Trends?

Market Size and Growth Rate:

• Estimated global market for norepinephrine formulations is valued at approximately USD 150 million in 2022.
• Compound annual growth rate (CAGR) projected between 5% and 7% over the next five years.
• North America accounts for roughly 60% of the market, with Asia-Pacific expected to be the fastest-growing segment.

Revenue Breakdown:

Region	2022 USD (millions)	CAGR (2023–2027)	Projected 2027 USD (millions)
North America	90	6%	132
Europe	30	4.5%	38
Asia-Pacific	20	8%	31
Rest of World	10	4%	12

Cost Dynamics:

• Manufacturing costs stabilize with increased generic competition.
• R&D investments pivot toward formulation improvements and new delivery methods.
• Supply chain costs fluctuate based on geopolitical factors and material availability.

Earnings Outlook:

• Premium pricing persists in developed markets due to hospital procurement contracts.
• Margins are under pressure from rising competition and price regulation.

How Do Regulatory and Patent Landscapes Impact Financial Outcomes?

• Many formulations are off-patent, affecting pricing strategies.
• Patent extensions or new indications could temporarily improve exclusivity and profitability.
• Regulatory agencies like FDA and EMA maintain rigorous approval standards, impacting time-to-market and associated costs.

What Are the Competitive and Market Entry Barriers?

• High barriers include hospital formulary approvals, generic drug competition, and strict regulatory compliance.
• Market entry requires significant investment in clinical trials, especially if new indications are sought.
• Existing relationships between pharmaceutical companies and healthcare providers influence market penetration.

Key Market Players:

• Pfizer (generic provider and branded formulary inclusion)
• Hospira (now part of Pfizer)
• Fresenius Kabi
• Sandoz (Novartis)

Investment and Strategic Considerations

• Focus on markets with high ICU admission rates and expanding critical care infrastructure.
• Consider generic portfolio expansion to capture cost-sensitive segments.
• Explore formulation innovations such as extended infusion formulations or stability improvements.

Conclusions

The financial trajectory for norepinephrine bitartrate in 5% dextrose hinges on critical care demand, pricing strategies, and regulatory developments. While the overall market shows steady growth, competitive pressures and regulatory hurdles influence profitability and market share.

Key Takeaways

• The global market size is roughly USD 150 million in 2022, with a CAGR of 5-7%.
• North America dominates, but Asia-Pacific's rapid growth offers opportunities.
• Pricing pressures and generic competition challenge profitability.
• Market entry requires navigating regulatory and formulary approval barriers.
• Strategic focus should target high-growth regions and formulation innovation.

FAQs

1. What are primary drivers for the growth of norepinephrine in critical care?
Increased ICU admissions, rising sepsis and shock cases, and expanding hospital use due to technological advances.

2. How does generic competition shape market prospects?
Generic formulations reduce prices, compress margins, and increase market penetration, especially in cost-sensitive regions.

3. Which regulatory factors influence commercialization?
FDA and EMA approval processes determine market entry timelines, with off-label uses expanding revenue potential.

4. What geographic trends are most significant?
North America leads in volume and revenue, with Asia-Pacific representing a significant growth area driven by healthcare infrastructure expansion.

5. What strategic moves can companies pursue?
Invest in formulation enhancements, expand into emerging markets, and build relationships with hospital formularies and distributors.

---

References

[1] Markets and Markets. (2022). Critical Care Drugs Market.
[2] Grand View Research. (2023). Vasopressors market analysis.
[3] U.S. Food and Drug Administration. (2022). Drug Approvals and Labeling.
[4] World Health Organization. (2023). Sepsis incidence and healthcare burden.
[5] IQVIA. (2022). Global pharmaceutical market data.